Immunohistochemical expression of androgen receptors in prostate carcinoma and benign prostatic hyperplasia

Sandra Trivunić Dajko; Jovo  Bogdanović; Aleksandra  Fejsa Levakov; Mirjana  Živojinov; Matilda  Djolai

doi:10.2298/VSP170629083T

Sandra Trivunić Dajko University of Novi Sad, Faculty of Medicine, Department of Pathology
Jovo Bogdanović University of Novi Sad, Faculty of Medicine, Department of surgery
Aleksandra Fejsa Levakov University of Novi Sad Department of Histology and Embriology; Clinical Centre of Vojvodina, Centre for Pathology and Histology
Mirjana Živojinov University of Novi Sad, Faculty of Medicine, Department of Pathology
Matilda Djolai University of Novi Sad, Faculty of Medicine, Department of Histology and Embriology, Novi Sad, Serbia; Clinical Centre of Vojvodina, Centre for Pathology and Histology

DOI: https://doi.org/10.2298/VSP170629083T

Keywords: prostate neoplasms;, receptors, androgen;, prostatic hyperplasia;, immunohistochemistry

Abstract

Background/Aim. Prostate carcinoma (PCa) and its parent organ are influenced by hormones, which is used for therapeutic purposes. Through androgen receptors (AR) androgens influence cell growth and function, proliferation, differentiation, apoptosis, lipid metabolism and secretory activity of the prostate, as well as development and progression of PCa. An antiandrogen therapy is carried out in patients with metastatic PCa, in order to block effects of androgens. By conducting immunohistochemical analysis of androgen receptors in the PCa tissue, we can assume how the tumour will react to an administered antiandrogen therapy, both in androgen-positive and androgen-negative, resistant tumours. Knowledge of the presence of AR in the tumour tissue may serve as a prognostic indicator in histopathological analysis. The aim of this study was to evaluate the expression of AR in patients with benign prostatic hyperplasia (BPH) and in those with PCa, before therapy. Methods. Immunohistochemical analysis was carried out by using anti-human AR monoclonal antibody AR441 (DAKO), and presence and intensity of AR were semi-quantitatively evaluated in 195 patients, 165 with BPH and 30 with PCa. Material for analysis was obtained by needle biopsy or transurethral resection of the prostate (TURP). Results. All secretory cells in patients with BPH were intensively androgen positive, while in patients with PCa they were mostly moderately to highly positive, but with foci of negativity. The observed negative correlation between AR and Gleason score and the International Society of Urologic Pathology (ISUP) grade group of PCa was not statistically significant. Conclusion. Study results indicate that PCa, before therapy, is androgen-dependent, with a high level of AR expression.

References

Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25(2): 276–308.

Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Molecular biology and physiology of the prostate. In: Berman DM, editor. Campbell-Walsh Urology. 10th ed. Philadelphia, PA: WB Saunders; 2011.

Poelaert F, Van Praet C, Beerens AS, De Meerleer G, Fonteyne V, Ost P, et al. The role of androgen receptor expression in the curative treatment of prostate cancer with radiotherapy: a pilot study. Biomed Res Int 2015; 2015: 812815.

Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972; 22(4): 232–40.

Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Hormonal therapy for prostate cancer. In: Berman DM, editor. Campbell-Walsh Urology. 10th ed. Philadelphia, PA: WB Saunders; 2011.

Horwich A, Parker C, de Reijke T, Kataja V. ESMO Guidelines Working Group. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl 6): vi106–14.

Vojinov S, Levakov I, Jeremić D, Živojinov S, Marušić G. Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade. Vojnosanit Pregl 2011; 68(4): 321–6. (Serbian)

Hansson J, Abrahamsson PA. Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Ann Oncol 2001;12(Suppl 2): S145–52.

Wetherill YB, Petre CE, Monk KR, Puga A, Knudsen KE. The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. Mol Cancer Ther 2002; 1(7): 515–24.

Hudes GR. Signaling inhibitors in the treatment of prostate cancer. Invest New Drugs 2002; 20(2): 159–72.

Noordzij MA, Bogdanowicz JF, van Krimpen C, van der Kwast TH, van Steenbrugge GJ. The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients. Department of Urology, Erasmus University, Rotterdam, Netherland. J Urol 1997; 158(5): 1880–4; discussion 1884-5.

Bortticelli AR, Pitino A, Botticelli D. Expression of neuroendocrine cells, androgen receptors and angiogenesis in prostate carcinoma. Pathologica 2002; 94(2): 107–11.

Renzo A, Botticelli A, Pitino A, Botticelli AR, Zaffe D. Prognostic relationship between immunohistochemical expression of neuroendocrine cells, androgen receptors and angiogenesis in prostate carcinoma. Pathologica 2002; 94(2): 109–12.

Qui YQ, Lauschner I, Braun PM. Androgen receptor expression in clinically localized prostate cancer: immunohistochemistry study and literature review: Asian J Androl 2008; 10(6): 855–63.

World Health Organization. World Health Statistics 2016: Monitoring health for the SDGs. Available from: www.who.int/gho/publications/world_health_statistics/2016/en/

Zhou M, Netto G, Epstein J. Uropathology: High-yerld patho-logy. Philadelphia, PA: Elsevier, Saunders; 2012.

Trivunić S, Budakov P, Vučković N, Živojinov M. Morphological parameters of prostatic adenocarcinoma. Med Pregl 2007; 60(11–12): 549–52.

Hansson J, Abrahamsson PA. Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Ann Oncol 2001; 12(Suppl 2): S145–52.

Wetherill Y, Petre CE. The xenoestrogen bisphenol A induces inappropiate androgen receptor activation and mitogenesis in prostatic adenocarcinoma. Mol Cancer Ther 2002; 1(7): 515–24.

Hudes GR. Signaling inhibitors in the treatment of prostate cancer. Invest New Drugs 2002; 20(2): 159–72.

Wilkström P, Marusic J, Stattin P, Bergh A. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate carcinoma. Prostate 2009; 69(8): 799–809.

Li R, Weeler T, Dai H, Frlov A, Thompson T, Ayala G. High level of androgen receptor is associated with aggressive clinico¬pathological feature and decreased biochemical recurrence-free survival in prostate cancer patients treated with radical prostatectomy. Am J Surg Pathol 2004; 28(7): 928–34.

Tamburrino L, Salvianti F, Marchiani S, Pinzani P, Nesi G, Serni S, et al. Androgen receptor (AR) expression in prostate cancer and progression of the tumor: Lessons from cell lines, animal mo¬dels and human specimens. Steroids 2012; 77(10): 996–1001.

Attard G, Cooper CS, de Bono JS. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 2009; 16(6): 458–62.

Hanahan D, Weinberg A. Hallmark of cancer: the next generation. Cell 2011; 144(5): 646–74.

Tadeka H, Akakura K, Masai M, Akimoto S, Yatani R, Shimazaki J. Androgen receptor content of the prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer 1996; 77(5): 934–40.

Segawa N, Mori I, Utsunomiya H, Nakamura M, Nakamura Y, Shan L, et al. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer. Pathol Int 2001; 51(6): 452–9.

Theodoropoulos VE, Tsigka A, Mihalopoulou A, Tsoukala V, Lazaris AC, Patsouris E, et al. Evaluation of the neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications. Urology 2005; 66(4): 332–7.

Osman WM, Abd El Atti RM, Abou Gabal HH. DJ-1 and androgen receptor immunohistochemical expression in prostatic carcinoma: a possible role in carcinogenesis. J Egypt Natl Canc Inst 2013; 25(4): 223–30.

Gordetsky J, Epstein J. Grading of prostatic adenocarcinoma: current state and prognostic implications. Diagn Pathol 2016; 11: 25.